NCT05198245View on ClinicalTrials.gov

Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy

Active, not recruitingOBSERVATIONAL
Enrollment

1

Participants

Timeline

Start Date

December 15, 2021

Primary Completion Date

April 17, 2028

Study Completion Date

April 17, 2028

Conditions
Migraine
Interventions
DRUG

Rimegepant

Rimegepant 75mg

DRUG

Various

Various

OTHER

No intervention

No intervention

Trial Locations (1)

10001

Pfizer, New York

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
collaborator

RTI Health Solutions

OTHER

collaborator

Optum, Inc.

INDUSTRY

lead

Pfizer

INDUSTRY

NCT05198245 - Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy | Biotech Hunter | Biotech Hunter